New Five-Year Lecanemab Data from Clarity AD Study Long-Term Extension Presented at CTAD 2026
PR Newswire•16/11/2026•18:00 ET
0
Key Highlights
- ➤Five-year continuous treatment produced a −2.05-point CDR-SB difference versus ADNI decline
- ➤Lecanemab reduced relative risk of next-stage disease progression by 36% versus ADNI
- ➤Lecanemab cut relative risk of moderate/severe AD progression by 49% versus ADNI
- ➤Low-tau patients: 62% showed CDR-SB improvement after five years
- ➤ARIA-E incidence declined from 13.5% in year one to 0.6% in year five
New Five-Year Lecanemab Data from Clarity AD Study Long-Term Extension Presented at CTAD 2026 PR Newswire
Benefits of continuous lecanemab treatment in early Alzheimer's disease accrue over time
Get started
Create a free account to read the full story.
